University of Florida Study Links Glucosamine to Dementia Progression

“In the United States, there are about 7 million people living with Alzheimer’s and millions more with related dementias such as Lewy body or frontotemporal dementia,” said senior author Ramon Sun, Ph.D., director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation at UF’s McKnight Brain Institute. “A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse.”

AI Analysis of Patient Health Records

To investigate whether popular supplements influence Alzheimer’s disease and related dementias, researchers Yi Guo, Ph.D., Jiang Bian, Ph.D., and their colleagues utilized artificial intelligence to evaluate deidentified UF Health patient records collected between 2012 and 2024. The retrospective analysis focused specifically on individuals diagnosed with mild cognitive impairment or Alzheimer’s disease and related dementias. Across both cohorts, 8% of patients reported taking glucosamine. This group included 2,750 people diagnosed with mild cognitive impairment and 1,896 people with Alzheimer’s disease and related dementias.

After adjusting for age, sex, and demographic variables, the team discovered that glucosamine consumption correlated with a 25% elevated risk of mild cognitive impairment advancing to dementia. Among individuals who already suffered from Alzheimer's disease and related dementias, glucosamine use was associated with a 25% higher mortality risk over a defined tracking period. Investigators did not observe this increased mortality association within the mild cognitive impairment group, indicating that the supplement may exert a more severe biological impact once dementia is already established.

Understanding the Observational Data and Cautions

Study authors emphasize that electronic health record associations do not establish direct causality. Matt Gentry, Ph.D., chair of UF’s Department of Biochemistry and Molecular Biology and a co-author of the study, noted that observational findings cannot definitively prove that glucosamine triggers disease progression, as unmeasured differences between supplement users and non-users could influence outcomes.

“The electronic health record data are very provocative,” Gentry said. “While it’s an association and not proof of causality, it does raise an important clinical question that now deserves much more attention.” Because millions of older adults regularly consume glucosamine for joint discomfort without a prescription, researchers stress that the findings must be rigorously tested through dedicated human clinical trials before definitive medical recommendations can be made.

A Cellular and Metabolic Mechanism

To explore the biological underpinnings of the statistical link, the research team investigated cellular mechanisms involving how the body processes nutrients. Their laboratory experiments pointed to a metabolic pathway where sugar structures attach to proteins. While this process is normal in healthy cell biology, the team found evidence that it becomes excessively active in Alzheimer’s disease.

By utilizing advanced spatial technology developed in Sun’s laboratory, scientists mapped thousands of molecules produced when cells break down foods and medications. This high-resolution mapping allowed investigators to track complex pathways related to glucosamine metabolism. Sun suggested that targeting these abnormal metabolic defects could eventually complement traditional Alzheimer’s research, which has historically focused primarily on amyloid-beta plaques accumulating between neurons and twisted tau protein tangles inside brain cells.